NCT06039696
Pathogenic Metagenomic Next-generation Sequencing to Optimize the Diagnosis of Decompensated Cirrhosis Infection
StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
Notable Enrollment target: 480 to 850v2 Show 4 more changesShow less
- Primary completion date: Jun 30, 2021 to Dec 30, 2024
- Study completion date: Apr 2024 to Mar 30, 2025
- Secondary endpoints: 5 to 7
- Study description expanded, about 112 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Positive rate of mNGS test in AD patients
Timeframe: at enrolment
Secondary (7)
90-day transplantation-free mortality
Incidence of acute kidney injury (AKI)
Proportion of hospital readmissions due to infections
Proportion of progression to SIRS or sepsis
Consistency with blood culture results
Show 2 moreShow less
Incidence of CMV reactivation
Rate of progression to acute-on-chronic liver failure (ACLF)
Arms and interventions
patients received mNGS test
After enrolment, patients will receive mNGS test.
Sites
1 site in 1 country
- Nanfang HospitalGuangzhou, Guangdong, China